The Shift To High Concentration mAbs: 3 Critical UF/DF Challenges And How To Solve Them

As high‑concentration monoclonal antibodies become essential for subcutaneous delivery and next‑generation therapies, UF/DF operations are being pushed into unfamiliar territory. Higher protein concentrations fundamentally alter process behavior, driving sharp increases in viscosity, tighter operating windows, and a greater risk of fouling and aggregation. Traditional TFF approaches often struggle under these conditions, leading to compromised performance and reduced process robustness. Take a practical look at how UF/DF changes as concentrations rise and why modern TFF platforms are better equipped to manage these challenges.

Explore the three most common UF/DF pain points associated with high‑concentration mAbs and learn actionable strategies to maintain control, protect product quality, and improve process efficiency as formulations continue to evolve.